Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing treatments for rare diseases in the United States. Its lead product candidate is KP1077, which includes two formulations: KP1077IH for idiopathic hypersomnia and KP1077N for narcolepsy, both in Phase 3 clinical trials. The company is also developing Celiprolol, an investigational treatment for vascular Ehlers Danlos syndrome, currently in Phase 3. Additionally, Zevra markets AZSTARYS, a once-daily medication for attention deficit and hyperactivity disorder (ADHD) in patients aged six and older. Its portfolio includes OLPRUVA for urea cycle disorders and MIPLYFFA for Niemann-Pick disease type C, an ultra-rare neurodegenerative disease. The company leverages its Ligand Activated Technology platform to develop these therapies.

Zevra Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ZVRA. Its shares are traded in United States Dollars (USD). The company is headquartered in Boston, Massachusetts, and primarily serves the U.S. market. As a U.S.-based company listed on a major American exchange, its financial reporting and stock trading are conducted in USD, making it accessible to domestic and international investors through U.S. brokerage accounts.

Zevra Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing therapies for rare diseases. Biotechnology firms like Zevra use biological processes and living organisms to create drugs, often targeting conditions with limited treatment options. The company's work in rare diseases places it at the intersection of innovative drug development and specialized medical needs, addressing unmet needs in areas such as sleep disorders, genetic conditions, and neurodegenerative diseases.

Zevra Therapeutics is headquartered in Boston, Massachusetts, United States. The company primarily serves the U.S. market, as indicated by its focus on addressing unmet needs for rare disease treatments in the United States. While its commercial operations are centered in the U.S., Zevra has collaboration and license agreements with international partners, such as Commave Therapeutics SA and Relief Therapeutics, Inc., which may support development and commercialization efforts globally. However, its core market and regulatory focus remain within the United States.

Zevra Therapeutics operates as a commercial-stage biotechnology company, generating revenue through the sale of its approved products and potentially through licensing agreements. Its commercial portfolio includes AZSTARYS for ADHD, OLPRUVA for urea cycle disorders, and MIPLYFFA for Niemann-Pick disease type C. The company also has a pipeline of product candidates in clinical trials, such as KP1077 for hypersomnia and narcolepsy, and Celiprolol for vascular Ehlers Danlos syndrome, which may generate future revenue upon approval. Additionally, Zevra has collaboration and license agreements, including one with Commave Therapeutics SA to develop and commercialize products containing SDX and d-methylphenidate, and a license agreement with Acer and Relief Therapeutics for OLPRUVA. These partnerships may provide milestone payments, royalties, or profit-sharing, contributing to its revenue model.